Sun Pharmaceutical Industries Ltd v. Solaris Pharma Corp

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Sun Pharmaceutical Industries, Ltd. (India) and Sun Pharmaceutical Industries, Inc. (Delaware)
  • Defendant: Solaris Pharma Corporation (New Jersey)
  • Plaintiff's Counsel: Rivkin Radler LLP
• Case Identification: 2:26-cv-04286, D.N.J., 04/22/2026
• Venue Allegations: Venue is asserted based on Defendant Solaris Pharma Corporation having a "regular and established place of business" in the District of New Jersey, where it allegedly committed acts of infringement and will commit future acts of infringement. The complaint also notes that Solaris has previously consented to jurisdiction in the district in a prior civil action.
• Core Dispute: Plaintiffs allege that Defendant's filing of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiffs' BromSite® ophthalmic solution constitutes an act of infringement of a reissued patent covering non-steroidal anti-inflammatory ophthalmic compositions.
• Technical Context: The technology relates to pharmaceutical formulations for ophthalmic use, specifically combining the non-steroidal anti-inflammatory drug (NSAID) bromfenac with a mucoadhesive polymer to provide sustained drug release and improved absorption in the eye.
• Key Procedural History: The patent-in-suit, RE50,218, is a reissue of U.S. Patent No. 8,778,999. Plaintiff Sun's branded product, BromSite® 0.075%, is covered by the '218 patent, which is listed in the FDA's Orange Book. The lawsuit was triggered by Defendant Solaris filing ANDA No. 220440 with a Paragraph IV certification, alleging that the '218 patent is invalid, unenforceable, and/or will not be infringed by its proposed generic product.

Case Timeline

Date	Event
2009-03-05	Priority Date for '218 Patent (Filing date of original '999 patent)
2014-07-15	Original U.S. Patent No. 8,778,999 Issues
2015-06-10	NDA for BromSite® Submitted
2016-04-08	FDA Approves BromSite® for Marketing
2024-11-26	U.S. Reissued Patent No. RE50,218 E Issues
2026-03-11	Solaris Sends Paragraph IV Notice Letter to Sun
2026-04-22	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Reissued Patent No. RE50,218 E - "Non-Steroidal Anti-Inflammatory Ophthalmic Compositions"

• Patent Identification: U.S. Reissued Patent No. RE50,218 E, "Non-Steroidal Anti-Inflammatory Ophthalmic Compositions," issued November 26, 2024.

The Invention Explained

• Problem Addressed: The patent's background section notes that prior ophthalmic delivery systems for the drug bromfenac have experienced drawbacks related to comfort, dosage control, consistency, and the timing of drug delivery '218 Patent, col. 1:20-27
• The Patented Solution: The invention is a topical ophthalmic formulation that combines the NSAID bromfenac with a "flowable mucoadhesive polymer" '218 Patent, abstract This polymer, exemplified by the DuraSite® system, is a lightly crosslinked carboxy-containing polymer that is liquid in the bottle but gels upon contact with the eye's tear fluid '218 Patent, col. 5:57-64 This gelling property increases the formulation's residence time on the ocular surface, facilitating a sustained release of bromfenac. The patent asserts this leads to higher absorption and retention of the drug in the eye's aqueous humor compared to conventional formulations, potentially allowing for less frequent dosing '218 Patent, col. 4:1-12
• Technical Importance: This technology aimed to enhance the therapeutic efficacy and patient compliance of topical bromfenac treatment by enabling a reduced dosing schedule (e.g., once daily) while maintaining effective drug concentrations at the site of inflammation '218 Patent, col. 4:5-8

Key Claims at a Glance

• The complaint alleges infringement of the "claims of the '218 patent" without specifying particular claims ('218 Patent, Compl. ¶26). Independent claims 1 and 50 are representative of the core composition claims.
• Independent Claim 1:
  • A topical ophthalmic composition formulated for application to the eye,
  • said composition comprising a therapeutically effective amount of bromfenac and a flowable cross-linked carboxy-containing polycarbophil mucoadhesive polymer,
  • wherein the composition has a viscosity in the range of about 1,000 to about 3,400 cps and a pH of about 7.4 to about 8.5,
  • wherein the viscosity is measured with a Brookfield cone and plate viscosity DV-II+ with the spindle No. CP-52 at 6 rpm.
• Independent Claim 50:
  • A topical ophthalmic composition formulated for application to the eye,
  • said composition comprising a therapeutically effective amount of bromfenac and a flowable crosslinked carboxy-containing polycarbophil mucoadhesive polymer,
  • wherein the composition has a viscosity in the range of about 1,000 to about 3,400 cps and a pH of about 7.4 to about 8.5;
  • the flowable mucoadhesive polymer is in an amount of about 0.5% to about 1.5% by weight of the composition;
  • the composition comprises from about 0.045% to 0.09% bromfenac by weight of the composition, and
  • wherein the viscosity is measured with a Brookfield cone and plate viscosity DV-II+ with the spindle No. CP-52 at 6 rpm.

III. The Accused Instrumentality

Product Identification

• Solaris's proposed generic "bromfenac ophthalmic solution, 0.075%," which is the subject of Abbreviated New Drug Application (ANDA) No. 220440 Compl. ¶2

Functionality and Market Context

• The accused product is a proposed generic version of Sun's commercially successful BromSite® product Compl. ¶1 By filing an ANDA, Solaris seeks FDA approval to market its product as a therapeutically equivalent substitute for BromSite® Compl. ¶2
• The basis for an ANDA filing is a representation to the FDA that the generic product has the same active ingredient, dosage form, strength, route of administration, and is bioequivalent to the reference listed drug, in this case, BromSite® Compl. ¶2 The complaint alleges that upon approval, Solaris intends to commercially manufacture, market, and sell its ANDA product in the United States Compl. ¶8

IV. Analysis of Infringement Allegations

The complaint is a notice pleading that does not contain a detailed, element-by-element infringement analysis. The central theory of infringement in this ANDA case is that because Solaris's proposed product is a generic version of BromSite® 0.075%, and because BromSite® is covered by the '218 patent, the proposed generic product will necessarily meet the limitations of the patent's claims Compl. ¶1 Compl. ¶2 The following chart summarizes this alleged correspondence for a representative claim.

No probative visual evidence provided in complaint.

'218 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A topical ophthalmic composition formulated for application to the eye...	Solaris's ANDA No. 220440 seeks approval for a generic bromfenac ophthalmic solution for application to the eye.	¶2	col. 9:1-3
...comprising a therapeutically effective amount of bromfenac...	The ANDA product is a 0.075% bromfenac ophthalmic solution, which is alleged to be a therapeutically effective amount for treating post-operative inflammation.	¶2	col. 9:3-4
...and a flowable cross-linked carboxy-containing polycarbophil mucoadhesive polymer...	As a generic version of BromSite®, which is based on the DuraSite® delivery system, the ANDA product is alleged to contain the claimed polycarbophil polymer.	¶1; ¶22	col. 10:41-43
...wherein the composition has a viscosity in the range of about 1,000 to about 3,400 cps and a pH of about 7.4 to about 8.5...	To be bioequivalent to BromSite®, the ANDA product is alleged to possess physical properties, such as viscosity and pH, that fall within the claimed ranges. The complaint does not allege specific values for the accused product.	¶2; ¶31	col. 9:7-9

• Identified Points of Contention:
  • Technical Questions: Solaris filed a Paragraph IV certification alleging non-infringement Compl. ¶24 This suggests Solaris will argue its formulation is materially different from the claimed invention. The key factual question will be whether the specific excipients, concentrations, pH, and viscosity detailed in Solaris's confidential ANDA submission fall within the scope of the patent claims as construed by the court.
  • Scope Questions: The interpretation of the term "about" as applied to the numerical ranges for viscosity, pH, and component concentrations will be a central issue. The dispute will likely focus on whether this term encompasses the specific properties of Solaris's formulation or if Solaris successfully "designed around" the patent by formulating its product outside these ranges.

V. Key Claim Terms for Construction

• The Term: "flowable cross-linked carboxy-containing polycarbophil mucoadhesive polymer"
• Context and Importance: This term defines the drug delivery vehicle, which is a core inventive concept. Infringement depends on whether the polymer system used in Solaris's ANDA product meets this definition. Practitioners may focus on this term because Solaris could argue its polymer, while a mucoadhesive, is not technically "polycarbophil" or has a different cross-linking structure than what is contemplated by the patent.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The specification references the polymer system more generally as "lightly crosslinked polymers of acrylic acid or the like" and incorporates by reference U.S. Patent No. 5,192,535 for a fuller description, suggesting the term is not limited to a single specific chemical entity '218 Patent, col. 5:20-22 '218 Patent, col. 5:31-33
  • Evidence for a Narrower Interpretation: The specification repeatedly uses the tradename "DuraSite®" and identifies "polycarbophil (Noveon® AA-1)" as the polymer '218 Patent, col. 5:23-24 '218 Patent, col. 5:34-35 A party could argue the claims should be limited to the specific properties of the exemplified DuraSite® system.
• The Term: "viscosity in the range of about 1,000 to about 3,400 cps"
• Context and Importance: This numerical range is a critical limitation for infringement. The meaning of "about" will determine the effective boundaries of the claim. Practitioners may focus on this term because a generic manufacturer could seek to formulate its product with a viscosity just outside the literal range, arguing non-infringement.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: Parties favoring a broader scope may argue that "about" should be interpreted to include values that are technically equivalent and account for standard measurement variability, consistent with the patent's purpose of providing a gel-like consistency in the eye.
  • Evidence for a Narrower Interpretation: The claim explicitly requires measurement with a specific instrument and protocol ("Brookfield cone and plate viscosity DV-II+ with the spindle No. CP-52 at 6 rpm") '218 Patent, col. 21:40-45 A party could argue that such precision narrows the interpretation of "about" and that the patentee intended to claim a precise and defined viscosity window. The patent's examples also provide a target viscosity of "1500 cps" '218 Patent, Table 2

VI. Other Allegations

• Indirect Infringement: The complaint alleges both induced and contributory infringement. The inducement claim is based on the allegation that Solaris knows of the patent and that its product's instructions and marketing will encourage infringing uses by patients and doctors Compl. ¶¶51-55 The contributory infringement claim is based on the allegation that Solaris's product is especially made for an infringing use and is not a staple article of commerce with substantial non-infringing uses Compl. ¶¶56-59
• Willful Infringement: Willfulness is alleged based on Solaris having actual knowledge of the '218 patent, at least since its listing in the Orange Book, and proceeding with its ANDA filing in deliberate disregard of Sun's patent rights Compl. ¶44 Compl. ¶48 Compl. ¶64

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of claim scope and formulation design: Did Solaris successfully "design around" the patent? This will require the court to first construe the scope of key limitations-particularly the term "polycarbophil" and the numerical ranges for viscosity, pH, and component concentrations modified by "about"-and then compare Solaris's confidential ANDA formulation against those construed claims.
• A parallel dispositive question will be one of validity: As raised in its Paragraph IV certification, Solaris will likely challenge the patent's validity over prior art Compl. ¶24 The key question for the court will be whether the specific combination of bromfenac with a polycarbophil-based delivery system within the claimed physical parameters was obvious or anticipated by earlier ophthalmic NSAID formulations.